KemPharm (KMPH) Misses Q2 EPS by 56c

KemPharm (NASDAQ: KMPH) reported Q2 EPS of ($0.70), $0.56 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.75 million.

For earnings history and earnings-related data on KemPharm (KMPH) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18